39 completed, 9 unknown, 3 recruiting, 2 terminated. 56 Phase 3, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 39, Unknown 9, Recruiting 3, Terminated 2, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 16 | Completed 8, Unknown 5, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow End Stage Renal Disease: new trials by email Literature Review of End Stage Renal Disease trials Research Report on End Stage Renal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation Pegcetacoplan, Placebo - Delayed Graft Function, End Stage Renal Disease | Phase 3 | Withdrawn | Apellis Pharmaceuticals, Inc. | 2026-05-18 | 2026-09-02 | |
| Study the Effect of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Level in Hemodialysis Patients Lactobacillus containing probiotic - End Stage Renal Disease | Phase 2 / Phase 3 | Unknown | Al-Azhar University | 80 | 2024-03-15 | 2024-05-20 |
| CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease CoQ10, Placebo, HB-HIIT - End Stage Renal Disease | Phase 3 | Recruiting | Vanderbilt University Medical Center | 156 | 2023-06-01 | 2026-01-02 |
| Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution - End Stage Renal Disease | Phase 3 | Recruiting | Iperboreal Pharma Srl | 170 | 2022-12-14 | 2026-03-24 |
| The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis Ascorbic acid, Tocopherol, Placebo capsule - Restless Legs Syndrome, End Stage Renal Disease | Phase 3 | Unknown | King Abdulaziz University | 160 | 2022-11-01 | 2022-08-24 |
| A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery Sirolimus - Complication of Renal Dialysis, End Stage Renal Disease | Phase 3 | Completed | Vascular Therapies, Inc. | 136 | 2022-08-26 | 2026-10-06 |
| DIalysis Symptom COntrol-Pruritus Outcome Trial Nabilone 0.5 MG Oral Capsule, Placebo Nabilone - End Stage Renal Disease, Pruritus | Phase 3 | Completed | University of Manitoba | 14 | 2022-08-02 | 2023-11-30 |
| Evaluation of The Effect of Rutin and Vitamin C on the Oxidative Stress in Hemodialysis Patients RUTA C 60 - End Stage Renal Disease | Phase 3 | Unknown | Ain Shams University | 105 | 2021-06-20 | 2021-07-19 |
| Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease Dapagliflozin, Placebo - Cardiovascular Diseases, End Stage Renal Disease | Phase 2 / Phase 3 | Withdrawn | Tan Tock Seng Hospital | 2021-06-01 | 2021-10-21 | |
| Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC) Triferic - End Stage Renal Disease | Phase 3 | Unknown | Rockwell Medical Technologies, Inc. | 150 | 2020-09-01 | 2021-04-21 |
| Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients Vitamin K2, Cholecalciferol (inactive vitamin D), Vitamin K2 and Cholecalciferol - End Stage Renal Disease | Phase 2 / Phase 3 | Unknown | Ain Shams University | 60 | 2019-09-01 | 2019-10-30 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric Citrate, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Panion & BF Biotech Inc. | 240 | 2019-06-19 | 2021-03-10 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric citrate tablet, Sevelamer carbonate tablet - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Sinomune Pharmaceutical Co., Ltd | 239 | 2019-05-24 | 2024-04-17 |
| DIalysis Symptom COntrol-Restless Legs Syndrome Trial Gabapentin, Ropinirole, Placebo Gabapentin - End Stage Renal Disease, Restless Legs Syndrome | Phase 3 | Completed | Population Health Research Institute | 52 | 2019-05-01 | 2022-09-21 |
| Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile Tacrolimus, Envarsus XR - End Stage Renal Disease | Phase 2 / Phase 3 | Recruiting | Roberto Gedaly | 78 | 2019-03-28 | 2026-03-24 |
| Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis Cognitive Behavioral Therapy for Insomnia, Trazodone, Placebo - Insomnia, End Stage Renal Disease | Phase 3 | Completed | University of Washington | 126 | 2018-09-19 | 2024-02-05 |
| Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Discontinuation (or not initiation) of Immunosuppressive Therapy, Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl® - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease | Phase 3 | Active not recruiting | Centre Hospitalier Departemental Vendee | 136 | 2018-02-02 | 2026-03-20 |
| Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Human Acellular Vessel (HAV), Arteriovenous fistula (AVF), Hemodialysis - Renal Failure, End Stage Renal Disease | Phase 3 | Completed | Humacyte, Inc. | 242 | 2017-09-29 | 2025-11-20 |
| Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus] - End Stage Renal Disease, Rejection of Renal Transplant | Phase 3 | Completed | Lorenzo Gallon | 29 | 2017-09-05 | 2023-04-10 |
| Communication During Hospitalization About Resuscitation Trial Informed Assent Discussion, Usual Care with Attention Control - Severe Life-limiting COPD, Severe Life-limiting Heart Failure | Phase 2 / Phase 3 | Completed | University of Vermont | 182 | 2016-12-01 | 2026-05-29 |
Showing 20 of 56. Sign in to see all of them.
Kidney Failure, Chronic (56) · Renal Insufficiency, Chronic (10) · Renal Insufficiency (9) · Kidney Diseases (6) · Hyperphosphatemia (4) · Arteriovenous Fistula (3) · Hyperparathyroidism, Secondary (3) · Inflammation (2) · Phosphorus Metabolism Disorders (2) · Restless Legs Syndrome (2) · Anemia (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Cardiovascular Diseases (1) · Delayed Graft Function (1) · Depression (1)
Chronic Disease (56) · Disease Attributes (56) · Female Urogenital Diseases (56) · Female Urogenital Diseases and Pregnancy Complications (56) · Male Urogenital Diseases (56) · Pathologic Processes (56) · Pathological Conditions, Signs and Symptoms (56) · Urogenital Diseases (56) · Urologic Diseases (55) · Kidney Diseases (50) · Renal Insufficiency (47) · Renal Insufficiency, Chronic (46) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Cardiovascular Diseases (5)
Cinacalcet (4) · ferric citrate (4) · Sirolimus (3) · Cognitive Behavioral Therapy (2) · Heparin (2) · Sevelamer (2) · Tacrolimus (2) · Vitamin E (2) · Acetylcysteine (1) · Arteriovenous Shunt, Surgical (1) · Ascorbic Acid (1) · Basiliximab (1) · Calcifediol (1) · Cholecalciferol (1) · Citric Acid (1)
Amgen (5) · Ain Shams University (2) · Humacyte, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Panion & BF Biotech Inc. (2) · Rockwell Medical Technologies, Inc. (2) · University of Washington (2) · Vascular Therapies, Inc. (2) · Western Galilee Hospital-Nahariya (2) · A.C. Abrahams (1) · Abbott (1) · Al-Azhar University (1) · Apellis Pharmaceuticals, Inc. (1) · Ark Therapeutics Ltd (1) · Ash Access Technology (1)
United States (26) · Canada (7) · Germany (5) · Egypt (3) · Israel (3) · Poland (3) · Puerto Rico (3) · United Kingdom (3) · China (2) · France (2) · Italy (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1)
Alan S. Kliger, M.D. (2) · Gerald J. Beck, Ph.D. (2) · Paul W. Eggers, Ph.D. (2) · Shamik Parikh, MD (2) · Sriram Iyer, MD (2) · A C Abrahams, MD (1) · Akinlolu Ojo, MD (1) · Alfredo R Zarate, MD (1) · Alistair J Ingram, MD (1) · Arduino Arduini, MD (1) · Baback Roshanravan, MD/MPH (1) · Catherine M Clase, MD (1) · David Collister, MD, PhD (1) · Dr. Michael Walsh, PhD,FRCPC(C) (1)
PMID 37651553, PMID 19339093, PMID 22422538, PMID 23149295, PMID 23332990, PMID 23970131, PMID 28094031, PMID 28301073, PMID 29621747, PMID 31826326, PMID 40576086, PMID 15689407, PMID 16105056, PMID 16724235, PMID 16758521, PMID 17848650, PMID 18793528, PMID 19272686, PMID 19628319, PMID 20616163, PMID 21091062, PMID 21122961, PMID 21200319, PMID 21775973, PMID 21981661, PMID 22360996, PMID 22845695, PMID 23344474, PMID 24078335, PMID 24593225, PMID 24833247, PMID 24840781, PMID 25402657, PMID 25884981, PMID 25953016, PMID 26621218, PMID 27774730, PMID 30802897, PMID 33081705, PMID 33294203, PMID 33586138, PMID 34845313, PMID 36791280, PMID 37662589, PMID 37916745, PMID 38224591, PMID 39205396, PMID 40080097, PMID 42613284
U01DK066597 (2), 2015 (1), 2019 (1), R01DK115468 (1), R44DK059062 (1)